Daniel Anderson
@D_AndersonID
Followers
165
Following
624
Media
0
Statuses
44
Assistant Professor of Pharmacology at the Medical College of Georgia via Emory Healthcare and UGA College of Pharmacy
Augusta, GA
Joined March 2019
RT @Wiki_Guidelines: Your Role: Review existing guidelines across all specialties to evaluate whether or not recommendations are based on h….
0
3
0
RT @Wiki_Guidelines: 📢📢📢Join our team appraising the level of evidence used to make consensus guideline recommendations across all specialt….
0
5
0
Do empiric, adjunctive aminoglycosides improve outcomes in critically ill patients with GNR bloodstream infections? Not according to our propensity-matched observational cohort study!.
Check out our manuscript in @antibioticsmdpi #IDTwitter #MedEd 🦠💊🙏🏽 . . @EudyJL @D_AndersonID @drdivsharma18 @MCG_AUG @mcg_id @WellstarHealth.
1
0
2
Excited to present our UTI @Wiki_Guidelines in @JAMANetworkOpen. It was an honor to work with so many brilliant clinicians and an organization whose charter I so strongly believe in.
2
0
8
RT @JAMANetworkOpen: This consensus statement creates a clinical guideline for the diagnosis and management of UTIs that addresses the gap….
0
78
0
RT @Wiki_Guidelines: We are delighted to announce the publication of UTI WikiGuideline in JAMA Network Open. Thank you to the 54 experts f….
0
38
0
@EudyJL Thanks to our amazing study team @strmltrofomonas @Pat_TuBROmycin @ViridansPharmD @SERGE_45_ABX and others.
1
0
3
IV-only patients were sicker at baseline (ICU admit but not CCI or Pitt) despite matching by source of infection. Median DOT ~2 weeks in both groups. PO patients received ~7 days of IV therapy. Was the second week of therapy necessary? @EudyJL.
1
0
3
Congrats to @AU_UGAPharmRes former PGY1 Carly Loudermilk on her manuscript evaluating sequential PO therapy for E. Faecalis BSI. No difference in clinical outcomes and shorter hospital LOS in sequential PO. @UGAPharmacy @mcg_id @blandman19 @AndreaSikora
journals.sagepub.com
Background: Intravenous (IV) antibiotics have historically been considered standard of care for treatment of bloodstream infections (BSIs). Recent literature ha...
2
10
33
RT @ABsteward: 🆕️🔥The largest real-world, multicenter study of dalbavancin use for Gram-positive BSI @NicholasRebold @IDpharmresearch and m….
link.springer.com
Infectious Diseases and Therapy - Long-acting lipoglycopeptides such as dalbavancin may have utility in patients with Gram-positive bloodstream infections (BSI), particularly in those with barriers...
0
46
0
Is there an exception to #ShorterIsBetter for critically ill patients with Gram-negative BSI? Not according to our propensity-matched cohort study @EudyJL @drdivsharma18 @zsulaiman13 @ABsteward @mcg_id @AU_UGAPharmRes
journals.sagepub.com
Background: Short courses of antibiotics (7-10 days) are effective for uncomplicated gram-negative bloodstream infections (GN-BSI). However, prior studies have ...
2
16
36
Thanks to the @UGAPharmacy students who make precepting such a joy! I’m humbled and honored to be recognized by this graduating class!.
Congratulations to the three outstanding preceptors selected to receive this year’s Preceptor of the Year Award:. - Dr. Daniel Anderson '18.- Dr. Amy Raufman Knauss '99.- Dr. Geneen Gibson. Thank you for the difference you make in the lives of our students every day!
0
2
27
RT @blandman19: I see you @ABC_PharmD! Double Antibiotic Coverage Does Not Improve Outcomes in Febrile Neutropenia.
0
5
0
Thanks to @Contagion_Live for sharing our teams work on treating ESBL UTIs!.
Both noncarbapenem β-lactams and #carbapenems produced good outcomes in #UTI from β-lactamase-producing #Enterobacterales #IDTwitter.
0
1
2
RT @accpinfdprn: 🔥 NEW in OFID 🔥. 👥 Retrospective cohort of admitted patients with ESBL UTI. 💊 non-carbapenem beta-lactams (NCBLs) vs. carb….
academic.oup.com
Extended-spectrum β-lactamase (ESBL)–producing organisms are commonly causative pathogens for urinary tract infections (UTIs). Carbapenems are recommended
0
23
0
RT @IDSAInfo: A new study in OFID suggests that carbapenems may not be necessary in the treatment of patients with urinary tract infections….
0
81
0
RT @AU_UGAPharmRes: Congratulations🎉 to Dr. Daniel Anderson our Infectious Diseases/Internal Medicine pharmacist for his most recent public….
0
5
0
Excited to share our article on management of ESBL UTIs. @sujitsuchindran @Albrechtazole @kaj401 @jestjac
academic.oup.com
Extended-spectrum β-lactamase (ESBL)–producing organisms are commonly causative pathogens for urinary tract infections (UTIs). Carbapenems are recommended
4
39
116